Literature DB >> 15356790

The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study.

Joan C Lo1, Kathleen Mulligan, Mustafa A Noor, Grace A Lee, Jean-Marc Schwarz, Carl Grunfeld, Morris Schambelan.   

Abstract

Pharmacologic doses of growth hormone (GH) reduce HIV-associated fat accumulation but may worsen glucose metabolism. We investigated the effects of a low dose of GH (1 mg per day) in HIV-infected men with fat accumulation and found that such treatment reduced total fat and increased lean body mass without significant changes in glucose tolerance or insulin sensitivity. Visceral adipose tissue (VAT) levels did not change significantly for the group as a whole, although a reduction in the VAT level was seen in patients with a greater VAT level at baseline.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356790      PMCID: PMC3170406          DOI: 10.1086/422725

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection.

Authors:  Leslie A Lenert; Martin Feddersen; Ann Sturley; Daniel Lee
Journal:  Am J Med       Date:  2002-08-15       Impact factor: 4.965

2.  Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting.

Authors:  Viva W Tai; Morris Schambelan; Heather Algren; Clara Shayevich; Kathleen Mulligan
Journal:  Clin Infect Dis       Date:  2002-10-23       Impact factor: 9.079

3.  Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; O Rouviere; F Bruno; R Avellaneda; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

4.  The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.

Authors:  J C Lo; K Mulligan; M A Noor; J M Schwarz; R A Halvorsen; C Grunfeld; M Schambelan
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

5.  Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation.

Authors:  Jean-Marc Schwarz; Kathleen Mulligan; Jeongae Lee; Joan C Lo; Michael Wen; Mustafa A Noor; Carl Grunfeld; Morris Schambelan
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

6.  "Buffalo hump" in men with HIV-1 infection.

Authors:  J C Lo; K Mulligan; V W Tai; H Algren; M Schambelan
Journal:  Lancet       Date:  1998-03-21       Impact factor: 79.321

7.  Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.

Authors:  Carol L Addy; Alina Gavrila; Sotirios Tsiodras; Kimberly Brodovicz; Adolf W Karchmer; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

8.  Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients.

Authors:  Donald P Kotler; Norma Muurahainen; Carl Grunfeld; Christine Wanke; Melanie Thompson; Michael Saag; Daena Bock; Gregg Simons; Joseph M Gertner
Journal:  J Acquir Immune Defic Syndr       Date:  2004-03-01       Impact factor: 3.731

9.  Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.

Authors:  Ellen S Engelson; Marshall J Glesby; Douglas Mendez; Jeanine B Albu; Jack Wang; Steven B Heymsfield; Donald P Kotler
Journal:  J Acquir Immune Defic Syndr       Date:  2002-08-01       Impact factor: 3.731

10.  Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution.

Authors:  Colleen Hadigan; James B Meigs; Peter W F Wilson; Ralph B D'Agostino; Benjamin Davis; Nesli Basgoz; Paul E Sax; Steven Grinspoon
Journal:  Clin Infect Dis       Date:  2003-03-20       Impact factor: 9.079

View more
  7 in total

1.  POTENTIAL NON-GROWTH USES OF rhIGF-I.

Authors:  Roy J Kim; Adda Grimberg
Journal:  Growth Genet Horm       Date:  2007-03

2.  Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Authors:  Janet Lo; Sung Min You; Bridget Canavan; James Liebau; Greg Beltrani; Polyxeni Koutkia; Linda Hemphill; Hang Lee; Steven Grinspoon
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

3.  Growth hormone resurrects adult human thymus during HIV-1 infection.

Authors:  Kiki Tesselaar; Frank Miedema
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

4.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 5.  Interventions for body habitus changes associated with HIV infection and its treatment.

Authors:  Pablo Tebas
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

6.  New and emerging agents in the management of lipodystrophy in HIV-infected patients.

Authors:  Eric Bonnet
Journal:  HIV AIDS (Auckl)       Date:  2010-09-17

7.  Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study.

Authors:  Christoforos D Giannaki; Giorgos K Sakkas; Christina Karatzaferi; Georgios M Hadjigeorgiou; Eleftherios Lavdas; Theodoros Kyriakides; Yiannis Koutedakis; Ioannis Stefanidis
Journal:  BMC Nephrol       Date:  2013-09-11       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.